GLOBAL KIDNEY CANCER MARKET (2024 - 2030)

The Kidney Cancer Market was valued at USD 7.81 billion in 2023 and is projected to reach a market size of USD 11.29 billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 5.4%.

The prevalence of kidney-related disorders has been on the rise, leading to a heightened demand for effective treatments and interventions. Concurrently, the escalating costs associated with healthcare services further emphasize the critical need for innovative and cost-effective solutions within the kidney market. Notably, the landscape is evolving with the introduction of new treatment developments, which not only address existing challenges but also pave the way for enhanced therapeutic options. Amidst this dynamic landscape, key players such as Eli Lilly and Company play a pivotal role in shaping the industry's trajectory. Their strategic initiatives, research and development endeavors, and market presence contribute significantly to the overall dynamics of the kidney market. Consequently, the market is expected to witness transformative developments, offering promising prospects for both patients and stakeholders alike.

Key Market Insights:

Kidney Cancer is a cancer that begins in the cells of the Kidney market Cancers. Kidney market Cancers are bean like shaped organs, each about the size of a fist. They are located behind the abdominal organs and on each side of the spine. One of the most common types of cancer in adults is renal cell carcinoma. At the advanced stage of the disease, removal of the cancer cells is vital to cure the kidney cancer disease with the help of medications.
Laparoscopic removal of the tumor-affected area is the new treatment method. Medicines can cure tumors at advanced stages of the disease. Cells in your Kidney Cancers can change and grow out of control. People with Kidney Cancer may have symptoms such as flank pain and high blood pressure. There are treatments for Kidney Cancers cancer like early detection is important for successful treatment.

Increased research and development expenditures from pharmaceutical companies are driving the market. Around 431,000 people worldwide are diagnosed with Kidney Cancer each year, according to a report by the International Kidney Cancer market Coalition. Over the forecast period, it is expected that the demand for Kidney Cancer diagnostics will increase due to the growing prevalence of the disease. Product launched by the key market players will boost and support the market expansion.

Kidney Cancer Market Drivers:

There has been an increase in the incidence of kidney cancer diseases driving the global market.

The growth of the Kidney Cancer market drugs market can be attributed to the increasing incidence of chronic kidney cancer disease. Around 10% of the population is affected by chronic kidney cancer disease. There are two types of cancer in the Kidney Cancers, renal cell carcinoma and renal pelvis cancer. Around 70 % of patients are of Renal Cell Carcinoma (RCC). The increasing burden of diseases among the population, especially the geriatric population, along with the introduction of advanced medical technologies for the treatment of various chronic health disorders is driving the demand for Kidney Cancer, worldwide. The support and assistance extended by the government of the source and the host destinations are predicted to significantly augment the market growth. People look for Kidney Cancer due to the expensive treatment or the long waiting time in their home country or the non-availability of any treatment. Therefore, to accomplish fast and affordable medical treatment people tend to opt for Kidney Cancer outside their home country. Moreover, the surging awareness regarding Kidney Cancer and the increasing affordability of advanced medical treatments is a primary factor behind the escalating demand for Kidney Cancer.

There is increased demand for Immunotherapies fueling the market size for kidney cancer.

The wide use of targeted therapies will be pushed by increasing preference for novel immunotherapies and immune-oncologic agents. The primary care in first and second-line RCC settings will be provided by programmed death-1 (PD-1) inhibitors. The combination regimen will be launched in the first-line setting to target major unmet needs, improve progression-free survival, overcome tumour resistance, and maintain the quality of life. The market growth is being enhanced by this treatment type.

The increasing governmental investment in medical infrastructure and maintenance is fuelling the Kidney Cancer Market growth.

The surging level of governmental investments to build robust, strong, and advanced healthcare facilities is propelling the Kidney Cancer market. The favourable government policies, growing investments for the improvement of air connectivity and other transport mediums, and several initiatives to promote Kidney Cancer are the main factors that contribute hugely to the development of the global market. Moreover, the easily available information regarding facilities and treatments of various diseases, cost, and best destinations for the treatment plays a chief role in spreading awareness regarding Kidney Cancer among the population. Furthermore, the obvious lack of an adequate number of specialized health professionals results in increased Kidney Cancer. Various health professionals undertake tourism activities to perform certain surgeries that require specialization or special knowledge to be conducted.

Kidney Cancer Market Restraints and Challenges:

The growth of the Kidney Cancer market drugs market could be hampered by the side effects of these drugs. The market can be hampered by effects such as loss of appetite. There are a variety of side effects that can be caused by cancer drugs. The type of drug used will affect the side effects. Some of the common side effects include fatigue, nausea and vomiting, and increased risk of infections.

Some private hospitals charge unreasonable fees for treatments and surgeries and patients who do not have their health insurance covered face a lot of problems eventually. And patients who have already covered themselves with a health plan face problems related to their insurance coverage policies and their reimbursement process as many insurance companies have complicated structures and sometimes may refuse to cover the patient’s full insurance sum for foreign treatments. And in some cases, they only cover the treatment expenses if they are cheaper in other countries and may not cover the airfare and miscellaneous expenses. Hence, people prefer to stay in their own respective countries for treatment which affects the Kidney Cancer industry. Also, people may face difficulties associated with language, documentation, and the visa approval process further hindering market growth. Additionally, one of the key challenges limiting the market’s expansion is the absence of appropriate follow-up care for patients. The market growth is hampered by the huge expenditure associated with these agents. Many patients are not able to afford the generic cancer treatments, market growth is hampered by it.

Kidney Cancer Market Opportunities:

There are several opportunities for market growth because of the rising approval from the FDA and other authorities.  For instance, Dohme Corp., KEYTRUDA was approved by the FDA for the treatment of patients suffering from Kidney Cancer cell carcinoma. The market expansion is enhanced by these factors.

Several organizations are funding rising expenditure that leads to the growth of the market.  China offers strong opportunities for market expansion due to the removal of price caps on all medicine categories and the ongoing Healthy China 2020 healthcare reform. The 12th Five- Year Plan of the Chinese government aims to improve the quality of life in the country. Strong unmet clinical needs and a large target base are expected to boost the market growth.

GLOBAL KIDNEY CANCER  MARKET REPORT COVERAGE:

Kidney Cancer Market Segmentation:

Market Segmentation: By Therapy:

• Targeted therapy
• Immunotherapy
• Chemotherapy
• Radiation
• Surgery

Based on the therapy, the targeted therapy segment accounted for the largest revenue share by 45% and has led the market in the year 2023. Several other factors such as rising patient awareness, growing demand for various anti-aging treatments, and the surging cost of cosmetic treatments and implants in developed nations are propelling the market growth. The more favourable side effect profile of targeted therapies compared to other therapies is one of the reasons for this. There is a growing list of new targeted therapies for cancer. The market for immunotherapy is expected to increase in the coming years. The dominance is due to its precision targeting, superior efficacy, and favourable side effect profile. Market expansion, a therapeutic paradigm shift, and increased pharmaceutical investment are some of the benefits of targeted therapy.  It is poised to play a bigger role in the future of treatment.

The immunotherapy segment captured a 30% share of the global market in 2022, making it the fastest growing segment. The growth is driven by its novel mechanism of action, durable responses, expanding indications, and promising combination therapies. Market expansion, a treatment paradigm shift, and increased patient advocacy are some of the benefits of immunotherapy.

 Market Segmentation: By Drug Class

• Angiogenesis Inhibitors
• mTOR Inhibitors
• Cytokines

A 48% share of the global market was captured by angiogenesis inhibitors in 2023. The dominance is due to their targeted approach, superior efficacy, and favourable side effect profile. Treatment outcomes can be improved by disrupting tumour blood supply and starving cancer cells.

Keytruda is the fastest-growing mAb in the market due to its efficacy across a broad spectrum of cancer types, including melanoma, non-small cell lung cancer, and head and neck cancer.

Its favourable safety profile, characterized by a lower incidence of severe side effects compared to traditional cancer therapies, has further solidified its position as a preferred treatment option.

The growing adoption of Pembrolizumab in settings where it is administered to patients after surgery to prevent cancer recurrence has contributed to its dominance. This mAb's remarkable success has not only spurred innovation in the mAb landscape, but also expanded the overall market by encouraging oncologists to embrace immunotherapy as a viable treatment modality.

Market Segmentation: By Distribution Channel:

• Hospitals
• Clinics
• Retail Pharmacies
• Others

Hospitals account for over half of total healthcare spending. There is a wide range of acute and chronic care services. Hospitals have a technological edge as they are at the forefront of technological advancement. Comprehensive care at hospitals includes primary, secondary, and tertiary care. Hospitals provide life-saving interventions for patients with critical and life-threatening conditions as they serve as the primary providers of emergency care.

The fastest growing segment after hospitals is the clinics segment, which holds 20% of the total healthcare spending. Factors such as accessibility and convenience, personalized care, and focus on chronic care management are attributed to the dominance. These factors have decentralized care into the community, reduced healthcare costs, increased access to specialists, and promoted integrated care.

The pharmacy plays a crucial role in providing essential services to patients with cancer.  The rising prevalence of chronic diseases, the aging population, and increasing healthcare costs are expected to drive the pharmacy market's growth. Pharmacy offer a variety of services to patients with cancer, such as medication therapy management, genetic testing, and oncology counseling.

Market Segmentation: Regional Analysis:

• North America
• Asia-Pacific
• Europe
• South America
• Middle East and Africa

North America region dominated the Kidney Market with a revenue of around 38.75% in 2023. The market growth can be owed to the increasing number of tourists in the U.S. for the treatment of Kidney Cancer treatment. A variety of factors including early adoption of advanced treatment options, well-established healthcare infrastructure, and a high prevalence of Kidney Cancer cases can be credited for this region's dominance. The region retains its market share because of strong research and development initiatives.  A high prevalence of Kidney Cancer, an advanced healthcare infrastructure, favorable reimbursement policies, leading pharmaceutical companies, and a strong clinical trial infrastructure are some of the factors that contribute to North America's role in the global Kidney Market.  These factors contribute to North America's market share and influence.

Europe is also an important market with a prominent market share. The factors such as the increasing development of medical facilities and organization in countries such as France, the U.K., and Spain and the rising trend of Kidney Cancer are driving the growth of the Kidney Market in Europe.

However, the Asia-Pacific region is anticipated to grow at the fastest CAGR of about 15.87% during the forecast period.  Asian countries are seen as the top choice for Kidney Cancer and travel owing to the low cost of treatments. India is considered to be popular tourist place for Kidney Cancer treatment. As a result, it is boosting the growth of the market in the Asia-Pacific region.There are a number of factors that contribute to Kidney Market growth in Asia-Pacific, including a rising prevalence of Kidney Cancer market, an expanding healthcare infrastructure, growing awareness and early detection, a favourable regulatory environment, and supportive government initiatives. The Asia Pacific region is experiencing a growth in the treatment of cancer.

COVID-19 Impact Analysis on the Kidney Market:

The market was negatively impacted by the reduction in R&D activities for Kidney Cancers cancer drugs. According to the data published by the National Center for Biotechnology Information in May 2020, the physicians were focused on developing a vaccine to prevent the spread of the disease. Extra critical care capacity for COVID-19 patients has led to a reduction in the capacity for surgery. COVID-19 had a big impact on the market.

According to data published by the National Center for Biotechnology Information, in May 2020 clinicians were focused on developing a vaccine to prevent the spread of the coronaviruses. Due to the spread of the coronavirus disease, the government of countries all over the world decided to lock down. Capacity for surgery has been reduced as theater space and ventilators have been requested to provide additional critical care capacity for patients with COVID-19. Patients were more reluctant to have surgery after anecdotal reports of patients developing COVID-19 in the hospital.

Latest Trends/ Developments:

The Kidney Market is reasonably split and fragmented with the existence of several global companies. These players are motivated to achieve higher market share by implementing different strategies, such as acquisitions, partnerships, and investments. Companies are also spending heftily on the development of improved products and infrastructure facilities alongside maintaining competitive pricing. This has further resulted in increased government engagement and the advancement of health tourism and infrastructure.

Additionally, the health industry recently has witnessed remarkable progress along with health tourism. These agencies work in cooperation with the patient’s medical condition as well as social and religious beliefs when arranging these trips, in this manner backing the Kidney Cancer sector in a salient manner. Health tourism specialists and travel agencies assist with all the mandatory travel and stay arrangements for tourists seeking medical care. They work together with the healthcare provider to plan out details of the travel, including visas, flights, lodging, insurance, currency exchange, etc. For instance, in 2020, OYO launched one-stop travel assistance, in collaboration with SRL Diagnostics, Indus Health Plus, and 1Mg for enabling tests through ICMR-approved pathology labs.

The market for Kidney market cancer is undergoing a period of rapid change due to the advancement of immunotherapy, targeted therapy, and combination therapies. Targeted therapies have shown particular effectiveness for clear cell renal cell carcinoma, which has emerged as a game-changer for advanced Kidney cancer market. Combining therapies are becoming more and more common, as it allows oncologists to tailor treatment to the individual patient's needs. Early detection and monitoring of Kidney market cancer can be done with liquid biopsy. New therapies are being developed for patients with rare Kidney Cancer market types.

Key Players:

• Pfizer Inc
• AstraZeneca
• Bristol-Myers Squibb Company
• Dr. Reddy's Laboratories Ltd
• Lupin
• Cipla Inc
• Aurobindo Pharma
• Fresenius SE & Co. KGaA
• Sanofi
• F. Hoffmann-La Roche Ltd
• Abbott
• In April 2023, FDA granted hurried approval to avelumab alongside axitnib (Inlyta) can be used in treatment for adults that suffer from Advanced RCC.